NYSE:ABBV - AbbVie Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $80.06 -1.09 (-1.34 %) (As of 05/26/2019 09:30 AM ET)Previous Close$80.06Today's Range$79.8701 - $81.1052-Week Range$75.62 - $103.16Volume3.87 million shsAverage Volume6.28 million shsMarket Capitalization$118.36 billionP/E Ratio10.12Dividend Yield5.27%Beta1.14 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Receive ABBV News and Ratings via Email Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:ABBV Previous Symbol CUSIP00287Y10 CIK1551152 Webhttp://www.abbvie.com/ Phone847-932-7900Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio0.91Price-To-Earnings Trailing P/E Ratio10.12 Forward P/E Ratio9.07 P/E Growth1.65 Sales & Book Value Annual Sales$32.75 billion Price / Sales3.61 Cash Flow$9.2448 per share Price / Cash Flow8.66 Book Value($5.29) per share Price / Book-15.13Profitability EPS (Most Recent Fiscal Year)$7.91 Net Income$5.69 billion Net Margins16.42% Return on Equity-221.09% Return on Assets20.45%Miscellaneous Employees30,000 Outstanding Shares1,478,332,000Market Cap$118.36 billion Next Earnings Date7/26/2019 (Estimated) OptionableOptionable AbbVie (NYSE:ABBV) Frequently Asked Questions What is AbbVie's stock symbol? AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV." How often does AbbVie pay dividends? What is the dividend yield for AbbVie? AbbVie declared a quarterly dividend on Thursday, February 21st. Investors of record on Monday, April 15th will be paid a dividend of $1.07 per share on Wednesday, May 15th. This represents a $4.28 dividend on an annualized basis and a yield of 5.35%. The ex-dividend date is Friday, April 12th. View AbbVie's Dividend History. How will AbbVie's stock buyback program work? AbbVie declared that its Board of Directors has initiated a share repurchase program on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued. How were AbbVie's earnings last quarter? AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.08. The company earned $7.83 billion during the quarter, compared to analysts' expectations of $7.81 billion. AbbVie had a negative return on equity of 221.09% and a net margin of 16.42%. The company's quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.87 EPS. View AbbVie's Earnings History. When is AbbVie's next earnings date? AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July 26th 2019. View Earnings Estimates for AbbVie. What guidance has AbbVie issued on next quarter's earnings? AbbVie updated its FY19 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of $8.73-8.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.67. AbbVie also updated its FY 2019 guidance to $8.73-8.83 EPS. What price target have analysts set for ABBV? 16 brokers have issued 1-year target prices for AbbVie's stock. Their forecasts range from $65.61 to $135.00. On average, they expect AbbVie's stock price to reach $94.5871 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View Analyst Price Targets for AbbVie. What is the consensus analysts' recommendation for AbbVie? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie. Has AbbVie been receiving favorable news coverage? Press coverage about ABBV stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the next several days. Are investors shorting AbbVie? AbbVie saw a decrease in short interest in April. As of April 30th, there was short interest totalling 21,822,012 shares, a decrease of 20.9% from the April 15th total of 27,575,807 shares. Based on an average daily volume of 7,260,751 shares, the days-to-cover ratio is presently 3.0 days. Currently, 1.5% of the shares of the stock are sold short. View AbbVie's Current Options Chain. Who are some of AbbVie's key competitors? Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG). What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD). Who are AbbVie's key executives? AbbVie's management team includes the folowing people: Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)Mr. Robert A. Michael, Sr. VP & CFO (Age 49)Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56) Who are AbbVie's major shareholders? AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.44%), Geode Capital Management LLC (1.45%), Northern Trust Corp (1.37%), FMR LLC (0.89%), Janus Henderson Group PLC (0.68%) and Morgan Stanley (0.61%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie. Which institutional investors are selling AbbVie stock? ABBV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Aristotle Capital Management LLC, Northern Trust Corp, PNC Financial Services Group Inc., BlackRock Inc., Ferguson Wellman Capital Management Inc., Handelsbanken Fonder AB and Clark Capital Management Group Inc.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie. Which institutional investors are buying AbbVie stock? ABBV stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Geode Capital Management LLC, Ellis Investment Partners LLC, Renaissance Technologies LLC, Ronna Sue Cohen, Parnassus Investments CA, Federated Investors Inc. PA and AQR Capital Management LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie. How do I buy shares of AbbVie? Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AbbVie's stock price today? One share of ABBV stock can currently be purchased for approximately $80.06. How big of a company is AbbVie? AbbVie has a market capitalization of $118.36 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe. What is AbbVie's official website? The official website for AbbVie is http://www.abbvie.com/. How can I contact AbbVie? AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900. MarketBeat Community Rating for AbbVie (NYSE ABBV)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 901 (Vote Outperform)Underperform Votes: 596 (Vote Underperform)Total Votes: 1,497MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: Trading based on a resistance level Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.